Your browser doesn't support javascript.
loading
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.
Assunção, Sheila Seleri; Sperling, Reisa A; Ritchie, Craig; Kerwin, Diana R; Aisen, Paul S; Lansdall, Claire; Atri, Alireza; Cummings, Jeffrey.
Afiliação
  • Assunção SS; US Medical Affairs - Neuroscience, Genentech, A Member of the Roche Group, South San Francisco, CA, USA. seleri.sheila@gene.com.
  • Sperling RA; Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Ritchie C; Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Scotland, UK.
  • Kerwin DR; Kerwin Medical Center, Dallas, TX, USA.
  • Aisen PS; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Lansdall C; University of Southern California Alzheimer's Therapeutic Research Institute, San Diego, CA, USA.
  • Atri A; F. Hoffmann-La Roche, Basel, Switzerland.
  • Cummings J; Banner Sun Health Research Institute, Sun City, AZ, USA.
Alzheimers Res Ther ; 14(1): 54, 2022 04 19.
Article em En | MEDLINE | ID: mdl-35440022
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article